Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2017

01-09-2017 | Review

Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers

Authors: Cheryl Lin, Rachel Clark, Pikuei Tu, Hayden B. Bosworth, Leah L. Zullig

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Login to get access

Abstract

Purpose

In the past decade, there has been an increase in the development and use of oral anti-cancer medications (OAMs), especially for breast cancer–the most prevalent cancer in women. However, adherence rates for OAMs are often suboptimal, leading to lower survival rate, increased risk of recurrence, and higher healthcare costs. Our goal was to identify potentially modifiable psychosocial facilitators and barriers that may be targeted to increase OAM adherence for breast cancer patients.

Methods

We systematically searched PubMed for studies published in the U.S. by June 15, 2016 that addressed the following: (1) OAMs for breast cancer; (2) medication adherence; and (3) at least one psychosocial aspect of adherence.

Results

Of the 1752 papers screened, 21 articles were included and analyzed. The most commonly reported motivators for adherence are patient-provider relationships (n = 11 studied, 82% reported significant association) and positive views and beliefs of medication (n = 9 studied, 89% reported significant association). We also identified consistent evidence of the impact of depression and emotions, perception of illness, concern of side effects, self-efficacy in medication management and decision making, knowledge of medication, and social support on OAM adherence.

Conclusions

Compared to traditional demographic, system, and clinical-related factors that have been well documented in the literature but are not easily changed, these cognitive, psychological, and interpersonal factors are more amendable via intervention and therefore could generate greater benefit in improving patient compliance and health outcomes. As OAMs shift treatment administration responsibility onto patients, continuous provider communication and education on illness and regimen are the keys to supporting patients’ medication behavior.
Literature
1.
go back to reference Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66(2):85–96PubMed Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66(2):85–96PubMed
2.
go back to reference Weingart SN et al (2008) NCCN Task Force Report: Oral chemotherapy. J Natl Compr Cancer Netw 6(Suppl 3):S1–S14 Weingart SN et al (2008) NCCN Task Force Report: Oral chemotherapy. J Natl Compr Cancer Netw 6(Suppl 3):S1–S14
3.
go back to reference Fallowfield L et al (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17(2):205–210CrossRefPubMed Fallowfield L et al (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17(2):205–210CrossRefPubMed
4.
go back to reference Liu G et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115CrossRefPubMed Liu G et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115CrossRefPubMed
5.
go back to reference Mazzoni E et al (2010) 22 Adherence to and persistence with an oral metronomic chemotherapy with capecitabine in heavily pretreated metastatic breast cancer (MBC) patients. Cancer Treat Rev 36:S101CrossRef Mazzoni E et al (2010) 22 Adherence to and persistence with an oral metronomic chemotherapy with capecitabine in heavily pretreated metastatic breast cancer (MBC) patients. Cancer Treat Rev 36:S101CrossRef
6.
go back to reference Benjamin L et al (2012) Physicians’ preferences for prescribing oral and intravenous anticancer drugs: a discrete choice experiment. Eur J Cancer 48(6):912–920CrossRefPubMed Benjamin L et al (2012) Physicians’ preferences for prescribing oral and intravenous anticancer drugs: a discrete choice experiment. Eur J Cancer 48(6):912–920CrossRefPubMed
7.
go back to reference Waterhouse DM et al (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189–1197CrossRefPubMed Waterhouse DM et al (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189–1197CrossRefPubMed
8.
go back to reference Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56–66CrossRefPubMed Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56–66CrossRefPubMed
9.
go back to reference Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478CrossRefPubMedPubMedCentral Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478CrossRefPubMedPubMedCentral
10.
go back to reference von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291–299CrossRef von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291–299CrossRef
12.
go back to reference McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768CrossRefPubMedPubMedCentral McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768CrossRefPubMedPubMedCentral
13.
go back to reference Makubate B et al (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524CrossRefPubMedPubMedCentral Makubate B et al (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524CrossRefPubMedPubMedCentral
14.
go back to reference Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537CrossRefPubMed Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537CrossRefPubMed
15.
go back to reference Wood L (2012) A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 16(4):432–438CrossRefPubMed Wood L (2012) A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 16(4):432–438CrossRefPubMed
16.
go back to reference Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652–661CrossRefPubMed Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652–661CrossRefPubMed
17.
go back to reference Culos-Reed SN et al (2000) Predictors of adherence to behavior change interventions in the elderly. Controll Clin Trials 21(5):S200–S205CrossRef Culos-Reed SN et al (2000) Predictors of adherence to behavior change interventions in the elderly. Controll Clin Trials 21(5):S200–S205CrossRef
18.
go back to reference Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–531CrossRefPubMed Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–531CrossRefPubMed
22.
go back to reference Verbrugghe M et al (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39(6):610–621CrossRefPubMed Verbrugghe M et al (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39(6):610–621CrossRefPubMed
23.
go back to reference van Londen GJ et al (2014) Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. Oncol Nurs Forum 41(6):660–668CrossRefPubMedPubMedCentral van Londen GJ et al (2014) Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. Oncol Nurs Forum 41(6):660–668CrossRefPubMedPubMedCentral
24.
go back to reference Rust C, Davis C (2011) Health literacy and medication adherence in underserved African-american breast cancer survivors: a qualitative study. Soc Work Health Care 50(9):739–761CrossRefPubMed Rust C, Davis C (2011) Health literacy and medication adherence in underserved African-american breast cancer survivors: a qualitative study. Soc Work Health Care 50(9):739–761CrossRefPubMed
25.
go back to reference Wells KJ et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130CrossRefPubMed Wells KJ et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130CrossRefPubMed
26.
go back to reference Neugut AI et al (2016) A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 158:127–138CrossRefPubMedPubMedCentral Neugut AI et al (2016) A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 158:127–138CrossRefPubMedPubMedCentral
27.
go back to reference Lebovits AH et al (1990) Patient noncompliance with self-administered chemotherapy. Cancer 65(1):17–22CrossRefPubMed Lebovits AH et al (1990) Patient noncompliance with self-administered chemotherapy. Cancer 65(1):17–22CrossRefPubMed
28.
29.
go back to reference Jacob Arriola KR et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103CrossRefPubMed Jacob Arriola KR et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103CrossRefPubMed
30.
go back to reference Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol 22(16):3309–3315CrossRefPubMed Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol 22(16):3309–3315CrossRefPubMed
31.
go back to reference Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8(2):155–161CrossRefPubMed Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8(2):155–161CrossRefPubMed
32.
go back to reference Friese CR et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931–939CrossRefPubMedPubMedCentral Friese CR et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931–939CrossRefPubMedPubMedCentral
33.
go back to reference Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220CrossRefPubMed Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220CrossRefPubMed
34.
go back to reference Hershman DL et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157(1):133–143CrossRefPubMedPubMedCentral Hershman DL et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157(1):133–143CrossRefPubMedPubMedCentral
35.
go back to reference Walker HE et al (2016) Perceptions, attributions, and emotions toward endocrine therapy in young women with breast cancer. J Adolesc Young Adult Oncol 5(1):16–23CrossRefPubMedPubMedCentral Walker HE et al (2016) Perceptions, attributions, and emotions toward endocrine therapy in young women with breast cancer. J Adolesc Young Adult Oncol 5(1):16–23CrossRefPubMedPubMedCentral
36.
go back to reference Rust CF, Davis C, Moore MR (2015) Medication adherence skills training for African–American breast cancer survivors: the effects on health literacy, medication adherence, and self-efficacy. Soc Work Health Care 54(1):33–46CrossRefPubMed Rust CF, Davis C, Moore MR (2015) Medication adherence skills training for African–American breast cancer survivors: the effects on health literacy, medication adherence, and self-efficacy. Soc Work Health Care 54(1):33–46CrossRefPubMed
37.
go back to reference Manning M, Bettencourt BA (2011) Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. Psychol Health 26(9):1173–1187CrossRefPubMed Manning M, Bettencourt BA (2011) Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. Psychol Health 26(9):1173–1187CrossRefPubMed
39.
go back to reference Liu Y et al (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836CrossRefPubMed Liu Y et al (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836CrossRefPubMed
40.
go back to reference Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439CrossRefPubMed Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439CrossRefPubMed
41.
go back to reference Llarena NC et al (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107(10):dvj202CrossRef Llarena NC et al (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107(10):dvj202CrossRef
42.
go back to reference Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328CrossRefPubMed Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328CrossRefPubMed
43.
go back to reference Bender CM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41(3):274–285CrossRefPubMedPubMedCentral Bender CM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41(3):274–285CrossRefPubMedPubMedCentral
45.
go back to reference Malbasa T, Kodish E, Santacroce SJ (2007) Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs 24(3):139–151CrossRefPubMed Malbasa T, Kodish E, Santacroce SJ (2007) Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs 24(3):139–151CrossRefPubMed
46.
go back to reference Richardson JL et al (1987) Path model of multidimensional compliance with cancer therapy. Health Psychol 6(3):183–207CrossRefPubMed Richardson JL et al (1987) Path model of multidimensional compliance with cancer therapy. Health Psychol 6(3):183–207CrossRefPubMed
47.
go back to reference Spoelstra SL et al (2016) Proof of concept of a mobile health short message service text message intervention that promotes adherence to oral anticancer agent medications: a randomized controlled trial. Telemed J E Health 22(6):497–506CrossRefPubMedPubMedCentral Spoelstra SL et al (2016) Proof of concept of a mobile health short message service text message intervention that promotes adherence to oral anticancer agent medications: a randomized controlled trial. Telemed J E Health 22(6):497–506CrossRefPubMedPubMedCentral
48.
go back to reference Tebbi CK et al (1988) The role of parent-adolescent concordance in compliance with cancer chemotherapy. Adolescence 23(91):599–611PubMed Tebbi CK et al (1988) The role of parent-adolescent concordance in compliance with cancer chemotherapy. Adolescence 23(91):599–611PubMed
49.
50.
go back to reference Zullig LL et al. (2017) Medication adherence: a practical measurement selection guide using case studies. Patient Education and Couns Zullig LL et al. (2017) Medication adherence: a practical measurement selection guide using case studies. Patient Education and Couns
51.
go back to reference Blay JY, Rutkowski P (2014) Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 40(2):242–247CrossRefPubMed Blay JY, Rutkowski P (2014) Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 40(2):242–247CrossRefPubMed
52.
go back to reference Kondryn HJ et al (2011) Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol 12(1):100–108CrossRefPubMed Kondryn HJ et al (2011) Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol 12(1):100–108CrossRefPubMed
53.
go back to reference Kanters S et al (2017) Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV 4(1):e31–e40CrossRefPubMed Kanters S et al (2017) Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV 4(1):e31–e40CrossRefPubMed
54.
go back to reference Viswanathan M et al (2012) Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 157(11):785–795CrossRefPubMed Viswanathan M et al (2012) Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 157(11):785–795CrossRefPubMed
55.
go back to reference Mathes T et al (2014) Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 40(1):102–108CrossRefPubMed Mathes T et al (2014) Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 40(1):102–108CrossRefPubMed
56.
go back to reference Bestvina CM, Zullig LL, Zafar SY (2014) The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol 10(14):2189–2199CrossRefPubMed Bestvina CM, Zullig LL, Zafar SY (2014) The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol 10(14):2189–2199CrossRefPubMed
Metadata
Title
Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers
Authors
Cheryl Lin
Rachel Clark
Pikuei Tu
Hayden B. Bosworth
Leah L. Zullig
Publication date
01-09-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4317-2

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine